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Conclusions 
 This review represents a first approach to summarize the information generated by 
the increasing number of population pharmacokinetic analyses for clinical practice.  
 A single combined range of expected imatinib concentrations can be useful to 
evaluate adherence & absorption problems, or drug-drug interactions, especially if no 
validated in-house model is available.  
 The PK-PD summary can additionally be useful to assist dosage decisions in case of 
suboptimal response and adverse events. However, a definite therapeutic range has to 
be formally validated by a prospective randomized controlled TDM-trial.  
 Systematic literature review (MEDLINE) of 
 Imatinib PPK & 
 Imatinib PK-PD relationships 
 Simulation-based meta-regression (with-
out specific study weighting). 
  
Imatinib is a first-line drug for CML and is 
characterized by a considerable pharmaco-
kinetic variability. 
Population pharmacokinetic (PPK) and 
pharmacokinetic-pharmacodynamic (PK-PD) 
studies have been increasingly performed.  
Simulation-based systematic review of imatinib population pharmacokinetics 
and PK-PD relationships in chronic myelogenous leukemia (CML) patients 
 
Methods 
Results 
Summary of imatinib population pharmacokinetics  expected concentration range (=reference range)  
Summary of imatinib PK-PD relationships  therapeutic suitability of Ctrough (potential therapeutic range) 
Introduction 
1) DATA: Nine population pharmacokinetic (PPK) 
models were identified and used to simulate 
concentration-time profiles of 1000 individuals each.  
Black shaded area: high density of concentrations 
(_highly expected). Grey shaded area: low density of 
concentrations (_concentrations less expected).  
 
Simulated dose: 400_mg/24h (=standard_dosage); 
Structural_kinetic_parameters:_D1, CL/F, V/F (standar-
dized to reference covariate values _see Table). 
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2) COMPARISON: Median concentration-time 
profiles (black lines) and 90% prediction intervals 
(gray lines: percentiles 5 and 95) of each PPK model, 
derived from simulations. 
9 PPK  
models 
1 reference 
range 
PK-PD 
relationships 
over 
reference  
range of 
Cmin 
3) COMBINATION: Reference concentration 
range, derived from the pooled data from the 9 
simulations: Median concentration-time profile (black 
line) 50% (dashed lines) and 90% (grey lines) prediction 
interval. Unexpected high or low concentrations may be 
partly explained by covariates ( see Table). 
Objective 
Covariate: reference 
(used for simulations) 
Covariate effect:  
Concentration  or  
[% change in CL/F; range] 
Body weight: 70 kg 105 kg:  [+13 to +72%]  
35 kg:  [-16 to -60%]  
Age: 50 years 87.5 y:  [-26%]  
25 y:  [+18%]  
Gender: male female:  [ -18%]  
Disease type: CML GIST:  [-10%]  
Albumin: 45 g/L 30 g/L:  [-23 to -49%]  
AGP: 0.9 g/L 1.5 g/L:  [-23 to -28%]  
White blood cells: 8 G/L 20 G/L:  [-9 to -32%]  
Granulocytes: 4.5 G/L 2 G/L:  [+59%]  
Hemoglobin: 14 g/L 9 G/L:  [-33%]  
ABCG2 (bcrp): wildtype heterozygous:  [-22%]  
Occasion: steady state day 1:  or  [-25 to +38%] 
6 PK-PD studies 
identified 
1 summary  
PK-PD relationship 
linear meta-regression  
 
1. Transformation of [%] into log-odds 
2. Linear regression model: log-odds ~ Cmin 
3.  Transformation of predicted log-odds into [%] 
non-
parametric 
regression 
2) COMPARISON: [%] with PD outcomes ~ 
Cmin, plotted for each of the 6 identified studies. 
  
––  (optimal early response)  
· · ·· · ·  (anemia), · · ·· · ·  (rash), · · ·· · ·  (fluid retention)  
 
Studies: 1: Peng 2004; 2: Singh 2009; 3: Sohn 2011; 4: 
Larson 2008; 5: Guilhot 2012; 6: Picard 2007. 
3) COMBINATION: The probability to achieve 
optimal early response was predicted to increase 
from 62% to 87% (+25%) by increasing Ctrough from 
520 to 1390 ng/mL (=summary inter-quartile range of 
Ctrough, standard dosage of 400mg/24h). Estimated odds 
ratio for doubling Ctrough: 2.7. blue area: 95% confidence 
interval.  
Table: Reference covariate values used for simulations 
and summary of covariate effects  altered expected 
concentration range. AGP: α1-acid glycoprotein 
1) DATA: Six relevant PK-PD studies were 
identified and proportions [%] of PD outcomes ~ Cmin 
were used as reported, or simulated from the 
distribution reported for responders and non-responders, 
respectively (3-4 points per study).  
 
Optimal early response is correlated to improved survival 
and includes complete hematologic response after 1-3 
months, and partial or complete cytogenetic response at 
6 and 12 months, respectively. 
PK measure:  
Imatinib trough 
concentration (Ctrough)  
 
PD outcome:  
Proportion [%] with 
optimal early response 
& adverse events 
 
Adverse event reporting was too heterogeneous to 
perform a meta-regression. The frequency of adverse 
events increased however consistently with Ctrough, but 
less than the response probability in the reference inter-
quartile range (IQR) of expected Ctrough under standard 
dosage (400_mg/24h) 
reference percentile (400_mg/24h) reference percentile (400_mg/24h) 
+ 25% 
Imatinib trough concentration [ng/ml] Imatinib trough concentration [ng/ml] 
